<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="7057540 pmid: 32051288jitc-2019-000276 doi: 10.1136/jitc-2019-000276 : Commentary: 1506 Management of" exact="hepatitis" post="B in the era of checkpoint inhibition DutcherJanice[], Cancer"/>
 <result pre="of hepatitis B in the era of checkpoint inhibition DutcherJanice[]," exact="Cancer" post="Research Foundation of NYNew YorkNew YorkUSA Correspondence to Dr"/>
 <result pre="made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.jitc-2019-000276.pdf Abstract" exact="Hepatitis" post="B virus (HBV) is a major global health concern,"/>
 <result pre="than 350 million people worldwide. Its management in the setting of" exact="cancer" post="treatment can be problematic, particularly with the use of"/>
 <result pre="the use of immunological treatment modalities, but also with chemotherapy." exact="Immunological" post="perturbations by chemo or immunotherapy have the potential to"/>
 <result pre="perturbations by chemo or immunotherapy have the potential to permit" exact="viral hepatitis" post="reactivation and acute hepatic failure. HBV management algorithms have"/>
 <result pre="by chemo or immunotherapy have the potential to permit viral" exact="hepatitis" post="reactivation and acute hepatic failure. HBV management algorithms have"/>
 <result pre="immunotherapy have the potential to permit viral hepatitis reactivation and" exact="acute" post="hepatic failure. HBV management algorithms have evolved, based on"/>
 <result pre="hepatic failure. HBV management algorithms have evolved, based on host" exact="tumor" post="factors, viral serological factors, and the specific antitumor agents"/>
 <result pre="HBV management algorithms have evolved, based on host tumor factors," exact="viral" post="serological factors, and the specific antitumor agents planned. As"/>
 <result pre="new agents enter the antitumor armamentarium, their impact on HBV" exact="infection" post="needs to be defined. Zhang et al provide data"/>
 <result pre="HBV antigen positive patients receiving checkpoint inhibitors (CPIs) in preventing" exact="hepatitis" post="reactivation, and offers guidance for such management in endemic"/>
 <result pre="highly effective in preventing reactivation. This is pertinent to Western" exact="cancer" post="therapy also, as a recent study has documented the"/>
 <result pre="a recent study has documented the silent existence of positive" exact="hepatitis" post="antigenemia among newly diagnosed cancer patients. Whereas antigen and"/>
 <result pre="the silent existence of positive hepatitis antigenemia among newly diagnosed" exact="cancer" post="patients. Whereas antigen and viral DNA screening is standard"/>
 <result pre="hepatitis antigenemia among newly diagnosed cancer patients. Whereas antigen and" exact="viral" post="DNA screening is standard of care in Asia and"/>
 <result pre="in Asia and Western Pacific oncology practice, evaluation for latent" exact="hepatitis" post="may become a necessary part of management worldwide as"/>
 <result pre="management worldwide as CPIs continue to expand their role. virology" exact="liver disease" post="Worldwide, more than 350 million people have chronic hepatitis B"/>
 <result pre="worldwide as CPIs continue to expand their role. virology liver" exact="disease" post="Worldwide, more than 350 million people have chronic hepatitis B"/>
 <result pre="role. virology liver disease Worldwide, more than 350 million people have" exact="chronic hepatitis" post="B virus (HBV) infection, with about 75% located in"/>
 <result pre="virology liver disease Worldwide, more than 350 million people have chronic" exact="hepatitis" post="B virus (HBV) infection, with about 75% located in"/>
 <result pre="evaluations have identified components leading to reactivation to include host" exact="tumor" post="type (and relationship to viral etiology), viral serological status,"/>
 <result pre="to reactivation to include host tumor type (and relationship to" exact="viral" post="etiology), viral serological status, the class of drug planned,"/>
 <result pre="to include host tumor type (and relationship to viral etiology)," exact="viral" post="serological status, the class of drug planned, and the"/>
 <result pre="all of these clinical settings, components leading to reactivation include" exact="viral" post="replication with direct viral cytotoxicity as well as immune"/>
 <result pre="settings, components leading to reactivation include viral replication with direct" exact="viral" post="cytotoxicity as well as immune reactivation following immune suppression"/>
 <result pre="immune-modulatory therapeutics enter the clinical arena, further assessment related to" exact="chronic" post="viral infection is necessary. Building on guidelines from the"/>
 <result pre="therapeutics enter the clinical arena, further assessment related to chronic" exact="viral infection" post="is necessary. Building on guidelines from the American Gastroenterological"/>
 <result pre="enter the clinical arena, further assessment related to chronic viral" exact="infection" post="is necessary. Building on guidelines from the American Gastroenterological"/>
 <result pre="chronic viral infection is necessary. Building on guidelines from the" exact="American" post="Gastroenterological Association,4 the American Society of Clinical Oncology (ASCO)"/>
 <result pre="necessary. Building on guidelines from the American Gastroenterological Association,4 the" exact="American" post="Society of Clinical Oncology (ASCO) has published provisional clinical"/>
 <result pre="(ASCO) has published provisional clinical opinions outlining the scenarios for" exact="viral" post="screening prior to cancer therapy.5 Both reports define patient-related"/>
 <result pre="clinical opinions outlining the scenarios for viral screening prior to" exact="cancer" post="therapy.5 Both reports define patient-related risk factors for latent"/>
 <result pre="screening recommendations continue to be discussed.2–5 The field of immune-mediated" exact="cancer" post="treatment has been greatly expanded by the development and"/>
 <result pre="checkpoint inhibitors (CPIs) as antitumor therapy. Importantly, the spectrum of" exact="malignant" post="diseases that has demonstrated response to anti-PD-1 directed agents"/>
 <result pre="these tumors are associated with viral-mediated oncogenesis, which may enhance" exact="susceptibility to" post="viral-mediated or immune-mediated injury. Numerous trials are ongoing globally"/>
 <result pre="area of clinical and translational research. In endemic geographic areas," exact="cancer" post="patients with chronic hepatitis viral infection are routinely managed"/>
 <result pre="and translational research. In endemic geographic areas, cancer patients with" exact="chronic hepatitis" post="viral infection are routinely managed with antiviral prophylaxis and"/>
 <result pre="translational research. In endemic geographic areas, cancer patients with chronic" exact="hepatitis" post="viral infection are routinely managed with antiviral prophylaxis and"/>
 <result pre="research. In endemic geographic areas, cancer patients with chronic hepatitis" exact="viral infection" post="are routinely managed with antiviral prophylaxis and treatment. Such"/>
 <result pre="In endemic geographic areas, cancer patients with chronic hepatitis viral" exact="infection" post="are routinely managed with antiviral prophylaxis and treatment. Such"/>
 <result pre="of the complex interactions with this class of drugs and" exact="chronic" post="HBV is yet to be fully elucidated. Now, in"/>
 <result pre="Zhang et al report a large retrospective safety evaluation of" exact="cancer" post="patients (multiple tumor types) with HBV surface antigen expression,"/>
 <result pre="report a large retrospective safety evaluation of cancer patients (multiple" exact="tumor" post="types) with HBV surface antigen expression, undergoing PD-1 inhibition"/>
 <result pre="HBV reactivation.7 Their study involved 114 patients with known HBV" exact="infection" post="and with serial measurements of HBV serological and viremic"/>
 <result pre="measurements of HBV serological and viremic status. Diagnoses included 24%" exact="hepatocellular carcinoma" post="(HCC), 8% lymphoma, and 68% others (including many tumor"/>
 <result pre="of HBV serological and viremic status. Diagnoses included 24% hepatocellular" exact="carcinoma" post="(HCC), 8% lymphoma, and 68% others (including many tumor"/>
 <result pre="hepatocellular carcinoma (HCC), 8% lymphoma, and 68% others (including many" exact="tumor" post="types known responsive to CPIs). One-third of patients had"/>
 <result pre="weeks of antiviral therapy. There was no significant correlation with" exact="tumor" post="type and HBV reactivation. The primary risk factor for"/>
 <result pre="no significant correlation with tumor type and HBV reactivation. The" exact="primary" post="risk factor for reactivation was lack of antiviral prophylaxis."/>
 <result pre="antiviral prophylaxis. Zhang et al additionally evaluated the development of" exact="hepatitis" post="in all 114 patients treated with CPIs.7 They describe"/>
 <result pre="all 114 patients treated with CPIs.7 They describe all grade" exact="hepatitis" post="in 35 patients (30.7%), and categorized these as HBV-related"/>
 <result pre="hepatitis in 35 patients (30.7%), and categorized these as HBV-related" exact="hepatitis" post="in five patients (4.4%) and immune-related hepatitis in 15"/>
 <result pre="these as HBV-related hepatitis in five patients (4.4%) and immune-related" exact="hepatitis" post="in 15 patients (13.2%). They state that other hepatotoxicity"/>
 <result pre="patients (13.2%). They state that other hepatotoxicity was due to" exact="disease" post="progression in the liver (nine patients) or to cytotoxic"/>
 <result pre="(nine patients) or to cytotoxic drugs (six patients). Grade 3/4" exact="hepatitis" post="was noted in four each with HBV-related hepatitis and"/>
 <result pre="Grade 3/4 hepatitis was noted in four each with HBV-related" exact="hepatitis" post="and immune-related hepatitis, as well as one each due"/>
 <result pre="hepatic lesion progression. Twenty of 35 patients with all grade" exact="hepatitis" post="had complete normalization of liver enzymes after a median"/>
 <result pre="progression. Twenty of 35 patients with all grade hepatitis had" exact="complete" post="normalization of liver enzymes after a median of 3.5"/>
 <result pre="of 35 patients with all grade hepatitis had complete normalization" exact="of liver" post="enzymes after a median of 3.5 weeks of antiviral"/>
 <result pre="weeks of antiviral treatment. Six patients required steroids for immune-related" exact="hepatitis" post="and none experienced HBV reactivation. These findings provide useful"/>
 <result pre="reactivation. These findings provide useful guidelines for the management of" exact="cancer" post="patients with chronic viral hepatitis or viral antigen positivity"/>
 <result pre="provide useful guidelines for the management of cancer patients with" exact="chronic" post="viral hepatitis or viral antigen positivity who are candidates"/>
 <result pre="useful guidelines for the management of cancer patients with chronic" exact="viral hepatitis" post="or viral antigen positivity who are candidates for treatment"/>
 <result pre="guidelines for the management of cancer patients with chronic viral" exact="hepatitis" post="or viral antigen positivity who are candidates for treatment"/>
 <result pre="the management of cancer patients with chronic viral hepatitis or" exact="viral" post="antigen positivity who are candidates for treatment with CPIs."/>
 <result pre="in terms of suppression of reactivation and management of immune-related" exact="hepatitis" post="and suggests that careful viral monitoring will allow ongoing"/>
 <result pre="reactivation and management of immune-related hepatitis and suggests that careful" exact="viral" post="monitoring will allow ongoing treatment. Limitations of the Zhang"/>
 <result pre="management among either group. Additionally, there was no quantitation of" exact="viral" post="DNA among those already receiving antiviral prophylaxis (simply called"/>
 <result pre="to anti-PD-1 treatment. Prospective clinical trials are ongoing, in which" exact="chronic hepatitis" post="viral carriers are required to receive antiviral therapy. In"/>
 <result pre="anti-PD-1 treatment. Prospective clinical trials are ongoing, in which chronic" exact="hepatitis" post="viral carriers are required to receive antiviral therapy. In"/>
 <result pre="treatment. Prospective clinical trials are ongoing, in which chronic hepatitis" exact="viral" post="carriers are required to receive antiviral therapy. In these"/>
 <result pre="In these trials, patients with HCC are routinely screened for" exact="viral" post="markers which are utilized to monitor the course of"/>
 <result pre="described with positive HBV antigen undergoing PD-1 inhibition therapy had" exact="cancer" post="diagnoses other than HCC, including nasopharyngeal, melanoma, and non-small"/>
 <result pre="diagnoses other than HCC, including nasopharyngeal, melanoma, and non-small cell" exact="lung cancer," post="among others. The approach in Asia is to screen"/>
 <result pre="among others. The approach in Asia is to screen all" exact="cancer" post="patients, regardless of diagnosis, for hepatitis virus infection, given"/>
 <result pre="is to screen all cancer patients, regardless of diagnosis, for" exact="hepatitis" post="virus infection, given the known high prevalence. This practice"/>
 <result pre="to screen all cancer patients, regardless of diagnosis, for hepatitis" exact="virus infection," post="given the known high prevalence. This practice remains a"/>
 <result pre="remains a question in other parts of the world, although" exact="viral" post="screening prior to anti-CD20 therapy has become more common"/>
 <result pre="West. A recent study of more than 3000 newly diagnosed" exact="cancer" post="patients undergoing treatment at nine academic and nine community"/>
 <result pre="community oncology institutions affiliated with the US Southwest Oncology Group" exact="Cancer" post="Research network reported on the prevalence of HBV, hepatitis"/>
 <result pre="Group Cancer Research network reported on the prevalence of HBV," exact="hepatitis" post="C virus (HCV), and HIV infection among persons newly"/>
 <result pre="on the prevalence of HBV, hepatitis C virus (HCV), and" exact="HIV infection" post="among persons newly diagnosed with cancer.10 As noted in"/>
 <result pre="the prevalence of HBV, hepatitis C virus (HCV), and HIV" exact="infection" post="among persons newly diagnosed with cancer.10 As noted in"/>
 <result pre="As noted in this report, currently, in the US universal" exact="hepatitis" post="viral screening is not routine in oncology practice. However,"/>
 <result pre="noted in this report, currently, in the US universal hepatitis" exact="viral" post="screening is not routine in oncology practice. However, among"/>
 <result pre="among the screened patients, the observed rate of prior HBV" exact="infection" post="was 6.5% and chronic HBV was 0.6%. The observed"/>
 <result pre="the observed rate of prior HBV infection was 6.5% and" exact="chronic" post="HBV was 0.6%. The observed rate of prior HCV"/>
 <result pre="chronic HBV was 0.6%. The observed rate of prior HCV" exact="infection" post="was 2.4%. Importantly, eight patients with chronic HBV and"/>
 <result pre="of prior HCV infection was 2.4%. Importantly, eight patients with" exact="chronic" post="HBV and 22 patients with HCV were newly diagnosed"/>
 <result pre="23 patients with HCV had no identifiable risk factors for" exact="viral infection." post="The authors conclude that in view of their study"/>
 <result pre="of their study defining a level of unawareness of prior" exact="viral infection" post="at the time of cancer diagnosis, screening for HBV"/>
 <result pre="their study defining a level of unawareness of prior viral" exact="infection" post="at the time of cancer diagnosis, screening for HBV"/>
 <result pre="of unawareness of prior viral infection at the time of" exact="cancer" post="diagnosis, screening for HBV and HCV may be warranted"/>
 <result pre="summary, Zhang et al demonstrates that antiviral therapy and careful" exact="viral" post="monitoring allows safe administration of CPIs to HBV infected"/>
 <result pre="viral monitoring allows safe administration of CPIs to HBV infected" exact="cancer" post="patients and demonstrates a management approach that is readily"/>
 <result pre="potentially a cost effective approach in the West, yielding new" exact="viral" post="carrier diagnoses in asymptomatic cancer patients.10 This is particularly"/>
 <result pre="in the West, yielding new viral carrier diagnoses in asymptomatic" exact="cancer" post="patients.10 This is particularly relevant given the increasing utilization"/>
 <result pre="utilization of CPIs in patients with a broad range of" exact="cancer" post="diagnoses. Contributors: JD is the sole author and has"/>
 <result pre="peer review: Commissioned; externally peer reviewed. References References 1DienstagJLHepatitis B" exact="virus infection." post="N Engl J Med Overseas Ed2008;359:1486–500.10.1056/NEJMra0801644 2PattulloVPrevention of hepatitis"/>
 <result pre="virus infection. N Engl J Med Overseas Ed2008;359:1486–500.10.1056/NEJMra0801644 2PattulloVPrevention of" exact="hepatitis" post="B reactivation in the setting of immunosuppression. Clin Mol"/>
 <result pre="gastroenterological association Institute guideline on the prevention and treatment of" exact="hepatitis" post="B virus reactivation during immunosuppressive drug therapy. Gastroenterology2015;148:215–9.10.1053/j.gastro.2014.10.03925447850 5HwangJP,"/>
 <result pre="SomerfieldMR, Alston-JohnsonDE, et al.Hepatitis B virus screening for patients with" exact="cancer" post="before therapy: American Society of clinical oncology provisional clinical"/>
 <result pre="al.Hepatitis B virus screening for patients with cancer before therapy:" exact="American" post="Society of clinical oncology provisional clinical opinion update. JCO2015;33:2212–20.10.1200/JCO.2015.61.3745"/>
 <result pre="EzemenariS, LiaukovichM, et al.A rare case of Pembrolizumab-Induced reactivation of" exact="hepatitis" post="B. Case Rep Oncol Med2018;2018:1–3.10.1155/2018/5985131 7ZhangX, ZhouY, ChenC, et"/>
 <result pre="Med2018;2018:1–3.10.1155/2018/5985131 7ZhangX, ZhouY, ChenC, et al.Hepatitis B virus reactivation in" exact="cancer" post="patients with positive hepatitis B surface antigen undergoing PD-1"/>
 <result pre="et al.Hepatitis B virus reactivation in cancer patients with positive" exact="hepatitis" post="B surface antigen undergoing PD-1 inhibition. J immunotherapy cancer."/>
 <result pre="Press2019;710.1186/s40425-019-0808-5 8El-KhoueiryAB, SangroB, YauT, et al.Nivolumab in patients with advanced" exact="hepatocellular carcinoma" post="(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation"/>
 <result pre="8El-KhoueiryAB, SangroB, YauT, et al.Nivolumab in patients with advanced hepatocellular" exact="carcinoma" post="(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation"/>
 <result pre="Lancet2017;389:2492–502.10.1016/S0140-6736(17)31046-2 9ZhuAX, FinnRS, EdelineJ, et al.Pembrolizumab in patients with advanced" exact="hepatocellular carcinoma" post="previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase"/>
 <result pre="9ZhuAX, FinnRS, EdelineJ, et al.Pembrolizumab in patients with advanced hepatocellular" exact="carcinoma" post="previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase"/>
 <result pre="2 trial. Lancet Oncol2018;19:940–52.10.1016/S1470-2045(18)30351-629875066 10RamseySD, UngerJM, BakerLH, et al.Prevalence of" exact="hepatitis" post="B virus, hepatitis C virus, and HIV infection among"/>
 <result pre="Oncol2018;19:940–52.10.1016/S1470-2045(18)30351-629875066 10RamseySD, UngerJM, BakerLH, et al.Prevalence of hepatitis B virus," exact="hepatitis" post="C virus, and HIV infection among patients with newly"/>
 <result pre="et al.Prevalence of hepatitis B virus, hepatitis C virus, and" exact="HIV infection" post="among patients with newly diagnosed cancer from academic and"/>
 <result pre="al.Prevalence of hepatitis B virus, hepatitis C virus, and HIV" exact="infection" post="among patients with newly diagnosed cancer from academic and"/>
 <result pre="C virus, and HIV infection among patients with newly diagnosed" exact="cancer" post="from academic and community oncology practices. JAMA Oncol2019;5:497–505.10.1001/jamaoncol.2018.643730653226"/>
</results>
